Differential Bio combines advanced microbiology, laboratory automation, and artificial intelligence to improve bioprocess optimization and scaling. virtual platform uses scale-down experiments and AI-driven models to optimize growth conditions and production processes for microbial systems. This aims to increase efficiency in bioproduction and improve results in terms of yield, costs, and product quality.
In the long term, the Pursue As “The Organism Modeling Company,” we aim to become the standard for in-silico bioprocess optimization – from the early research and development phase to industrial production.
Differential Bio addresses challenges of bioproduction
Biomanufacturing, which uses biological systems such as microbial cells to produce everything from food ingredients to pharmaceuticals, offers a sustainable alternative to conventional, often petroleum-based production methods. However, despite its potential, the industry faces a major hurdle. Scaling bioprocesses from the laboratory to the industrial level is slow and often prohibitively expensive.
Christian Spier, CEO of Differential Bio, explains:
"Biomanufacturing is key to a regenerative future, but scaling these processes remains a major bottleneck for the industry. But we're here to change that by equipping biomanufacturers with cutting-edge tools to reduce development times and costs and bring bio-based products to market faster than ever before."
Investors rely on future-oriented technology
The financing round was led by Ananda Impact Ventures and ReGen Ventures. Additional participation came from Carbon13, Climate Capital, Better Ventures, CDTM Ventures, and a group of angel investors.
Bernd Klosterkemper, Partner at Ananda Impact Ventures, highlights the potential of the technology:
"The Differential team immediately attracted us with their exceptional combination of deep technical expertise, innovative scientific approach, and visionary drive to deliver impactful solutions at scale. We believe their technology will redefine biomanufacturing by enabling faster and more efficient scaling of bio-based processes and accelerating the global transition to a sustainable, green, and circular economy."
And Tom McQuillen, Partner at ReGen Ventures, says:
"Biomanufacturing is hampered by a scaling crisis. By leveraging machine learning based on extensive phenotypic and biological process data, Differential has the potential to redefine large-scale biomanufacturing by enabling incremental reductions in cost and time to commercialization."
With the fresh capital, the startup plans to further develop its platform, expand its team, and acquire new customers in the food, cosmetics, and specialty chemicals sectors.
